Close this search box.

Introduction of Real-Time Motion Synchronization Technology on the Radixact® System

June 24, 2022
Stereotactic radiotherapy for lung cancer has seen an increase in the number of cases treated, especially in elderly patients. In addition, the indication for stereotactic body radiotherapy(SBRT) for oligometastatic cases is rapidly expanding, as well as an increasing number of SBRT treatments in the abdominal region. For SBRT in the abdominal region and lower lung field, measures against the respiratory motion are important. Synchrony® is a technology that enables tracking and irradiation of moving targets. It is expected to guarantee the dose to the moving tumor and reduce the irradiation volume of normal tissues. However, to provide safe and reliable treatment, it is necessary to understand the Synchrony mechanism and its characteristics. 

The Shizuoka Cancer Center, Japan has been delivering SBRT using Synchrony on the Radixact® Treatment Delivery System since 2021. 

Join Hideyuki Harada, M.D., Ph.D., and Tetsuya Tomida, MSc., who will share their initial experience utilizing Synchrony technology.

The presentation will include: 
– The commissioning process. What the Shizuoka Cancer Center has learned from patient QA and additional validation.
– CT simulation for Synchrony (Introduction of the Shizuoka Cancer Center method).
– Importance of Synchrony simulation
– Introduction of SBRT using Synchrony (Lung tumor: Lung with respiratory, Adrenal tumor: Fiducial respiratory)
– Introduction of cases in which Synchrony was judged to be unsuitable during the simulation and treatment period.

This webinar will provide practical and technical information for SBRT treatment delivery using Synchrony on the Radixact Treatment Delivery System.

Hideyuki Harada, M.D.

Hideyuki Harada, M.D., Ph.D., Chief, Division of Radiation Therapy, Shizuoka Cancer Center, Japan

Dr. Harada is the Chief, Radiation Oncologist, Division of Radiation Therapy, Shizuoka Cancer Center, Shizuoka, Japan, and he has held this position since 2015. Dr. Harada received his M.D., in 1999 and was awarded a Ph.D. in 2010, receiving both awards from Hamamatsu University School of Medicine. He is a board-certified member of the Japanese Board of Radiology – Therapeutic Radiology, the Japanese Board of Radiation Oncology, and the Japanese Board of Cancer Therapy. He is a member of the Japan Radiological Society, Japanese Society for Therapeutic Radiology and Oncology, Japan Society of Clinical Oncology, Japan Lung Cancer Society and International Member, American Society for Therapeutic Radiology and Oncology. His fields of expertise are in high-precision radiation therapy, lung cancer, sarcoma, and brain tumors.

Tetsuya Tomida, MSc.

Tetsuya Tomida, MSc., Radiologic Technologist, Medical Physicist, Quality Control Specialist, Division of Radiation Therapy, Shizuoka Cancer Center, Japan

Tetsuya Tomida is a Medical Physicist at Shizuoka Cancer Center, Japan since 2003. He graduated from Ibaraki Prefectural University of Health Sciences, Graduate School of Health Sciences, Master of Sciences in Radiological Sciences in 2003. His current areas of research are Flattening Filter Free Beam, respiratory migration velocity of tumors using 4DCT and setup errors. He has experience in proton therapy. He started up a CT co-located linac and studied the effect of setup errors on dose distribution. He has also carried out research on automatic exposure control of diagnostic CT, and research on ultra-early phase in contrast-enhanced MRI of the breast. 

Hiroshi Onishi, M.D.

Moderated by: Hiroshi Onishi, M.D., Professor, and Chairman, Department of Radiology, Vice-director of School Medicine, University of Yamanashi, Yamanashi, Japan

Prof. Hiroshi Onishi, is Professor and Chairman, Department of Radiology, University of Yamanashi, and Vice-director of School Medicine at the University of Yamanashi.

Prof. Hiroshi Onishi is a board member of JASTRO and is a chairman of the Health Insurance Committee. He is a specialist in SBRT, particularly for lung cancer. He first showed the minimum required dose of SBRT for stage I non-small cell lung cancer (NSCLC), and his papers have been referred to in the NCCN guideline for NSCLC.